MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$4,812K
EPS
-$0.03
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
NaN 6,608 3,681 2,765
Cost of royalties
NaN 80* 5 39
Research and development
NaN 8,238 3,271 3,106
General and administrative
NaN 4,852 4,191 4,560
Gain on impairment of intangible asset (note 6 and note 13)
NaN -14* 0 14,840
Total operating expenses
NaN 13,156 7,467 22,545
Loss from operations
NaN -6,548 -3,786 -19,780
Interest income, net
NaN 393 366 454
Loss on marketable equity securities, net
NaN -7 6 -2
Change in fair value of warrant liability
NaN -1,265 26,557 12,740
Foreign currency transaction gain (loss), net
NaN 482 219 1,678
Other income (expense), net
NaN 27 0 26
Total other income (expenses)
NaN 2,160 -25,966 -10,584
Loss before income taxes
NaN -428* NaN NaN
Income tax benefit
NaN -1,320* NaN NaN
Net gain
-4,789 892 -29,752 -30,364
Net (income) loss attributable to noncontrolling interest
23 41 29 100
Net gain attributable to lineage
-4,812 851 -29,781 -30,464
Basic EPS
-0.02 0.004 -0.13 -0.13
Diluted EPS
-0.03 0.004 -0.13 -0.13
Basic Average Shares
245,029,000 237,201,000 228,853,000 228,356,000
Diluted Average Shares
261,175,000 237,201,000 228,853,000 228,356,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net gainattributable to lineage-$4,812K (-16.26%↓ Y/Y)Net gain-$4,789K (-15.59%↓ Y/Y)Net (income) lossattributable to...$23K (675.00%↑ Y/Y)

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics, Inc. (LCTX)